A 2025 randomized clinical trial called the TARGET-D trial at Intermountain Health involving 630 patients found that targeting vitamin D3 supplementation to raise serum 25-hydroxyvitamin D levels above 40 ng/mL reduced the risk of recurrent heart attack by approximately 50% among patients who had experienced a heart attack within the previous month.
January 01, 2025
high
statistical
Result from the TARGET-D randomized clinical trial evaluating targeted vitamin D3 supplementation in recent heart attack survivors.
A 2025 randomized TARGET-D trial reported that 85% of the 630 enrolled patients who had experienced a recent heart attack had insufficient serum vitamin D3 levels at baseline.
January 01, 2025
high
statistical
Baseline vitamin D status among patients enrolled in the TARGET-D trial.
In the 2025 TARGET-D trial, more than half of participants required an initial oral vitamin D3 dose of 5,000 international units (IU) to reach serum 25-hydroxyvitamin D levels above 40 ng/mL.
January 01, 2025
high
statistical
Dosing information observed in the TARGET-D trial to achieve target serum vitamin D levels.